Navigation Links
Inovio Pharmaceuticals Licenses Non-DNA Vaccine Tumor Therapy Technology to OncoSec Medical
Date:3/15/2011

BLUE BELL, Pa., March 15, 2011 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that it has signed an agreement with OncoSec Medical Inc. (OTC Bulletin Board: ONCS.D) providing for the sale to OncoSec of certain non-DNA vaccine technology and intellectual property relating to electroporation technology useful for electrochemical and cytokine based immune therapies for treating solid tumors. OncoSec will pay Inovio an undisclosed purchase price for the assigned assets and cash fees and a royalty on commercial product sales.

Dr. J. Joseph Kim, Inovio's president and CEO, said: "As Inovio advances its leadership in the DNA vaccine field with several Phase II clinical studies for cervical dysplasia, leukemia, and hepatitis C virus therapies, we are pleased to enable third parties to commit their focus and resources to achieve the commercial potential of Inovio's non-DNA vaccine assets. Prior clinical testing of our selective electrochemical tumor treatment and cytokine cancer therapies produced promising results and we are excited to monetize this electroporation asset for these applications and see its advancement by OncoSec. We wish the company every success in this endeavor."

Mr. Punit Dhillon, OncoSec's president and CEO, said: "We are excited to conclude this agreement with Inovio to acquire this promising technology for locally targeted cancer treatments, which have previously achieved important clinical outcomes, and immediately begin the implementation of our clinical development and commercialization plan. There are millions of people in the US alone who face detrimental cosmetic, functional and pain outcomes resulting from the invasive treatments used today for various skin and other cancers – in addition, the nature of c
'/>"/>

SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Inovio Pharmaceuticals Closes $24.3 Million Registered Offering
2. University of Southampton and Inovio Pharmaceuticals Initiate Phase 2 Clinical Study to Evaluate Leukemia DNA Vaccine Using Electroporation Delivery Technology
3. Inovio Pharmaceuticals Dual-Antigen SynCon™ DNA Vaccine for Prostate Cancer Induces Robust Responses in Preclinical Trial
4. Inovio Pharmaceuticals Unveils Needle-free, Contactless Electroporation Technology for DNA Vaccine Delivery
5. Inovio Pharmaceuticals to Present at Partnering and Scientific Conferences
6. Inovio Pharmaceuticals to Present at Cowen & Co. Health Care Conference
7. Inovio Pharmaceuticals to Present at ROTH 23rd Annual Growth Stock Conference
8. Inovio Pharmaceuticals Partner ChronTech Initiates Phase II Clinical Trial of Hepatitis C Virus DNA Vaccine Using Inovios Electroporation Delivery Technology
9. OncoSec Medical Licenses Non-DNA Vaccine Tumor Therapy Technology from Inovio Pharmaceuticals
10. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... , Aug. 28, 2015  With the heroin ... reaching deadlier heights, Jacksonville -based Lakeview ... Hemphill is helping to explain why fentanyl is ... approximately 40 to 50 times more potent than pharmaceutical ... users as heroin, the risk of death skyrockets. ...
(Date:8/28/2015)... , Aug. 28, 2015  Delays in ... projects can slow down the decision-making process, resulting ... therefore, absolutely critical for biopharmaceutical companies to develop ... approval process for quicker and more meaningful insights. ... Best Practices, LLC, nearly three-quarters of benchmarked study ...
(Date:8/28/2015)... SAN FRANCISCO, Calif. , Aug. 28, 2015 /PRNewswire/ ... for the treatment of cancer, today announced the filing ... U.S. Securities and Exchange Commission (SEC) relating to a ... number of shares to be offered and the price ... CytomX intends to list its common stock under the ...
Breaking Medicine Technology:Lakeview Health's Dr. Philip Hemphill Explains Why Heroin Addicts Are Now Dying of Fentanyl Overdoses 2Expediting the Pharmaceutical Market Research Process for Faster Insights 2CytomX Files Registration Statement for Proposed Initial Public Offering 2
... Ph.D., will join the executive committee of Eli Lilly and ... Walsh will continue in her current role as Lilly,s ... Ph.D., chairman, president, and CEO, and working to ensure Lilly ... Walsh is a recognized thought leader in the ...
... June 30, 2011 Xlumena, Inc., a ... and endoscopic surgeon, announced today that it has received ... The NAVIX is a multi-function system that enables exchange-free ... endoscopic pancreatic pseudocyst drainage.  The NAVIX will join the ...
Cached Medicine Technology:Lilly Quality Leader Walsh Appointed to Company's Executive Committee 2Xlumena Receives CE Mark for NAVIX™, Second Product to Enter European Market 2
(Date:8/29/2015)... Viejo, CA (PRWEB) , ... August 29, 2015 , ... ... Pro X . Each preset contains 15 seconds of unique footage that users can ... that rise, fall, zoom, attract and more. Users can customize color, brightness, scale, speed, ...
(Date:8/29/2015)... ... 2015 , ... People who have heart or lung diseases, ... are at higher risk from wildfire smoke especially in Calgary, Alberta.Those with existing ... (arrhythmia or irregular heartbeat) are also sensitive to air pollution. , Tiny ...
(Date:8/29/2015)... ... August 29, 2015 , ... ... treating the localized area with stretching, soft tissue manipulation. Platelet rich plasma injections ... have shown through research to improve treatment outcomes. This localized treatment seems ...
(Date:8/29/2015)... (PRWEB) , ... August 29, 2015 , ... The popular ... James Earl Jones, recently announced that it will be devoting an entire short segment ... affecting millions of people around the globe on a daily basis, but recent advancements ...
(Date:8/29/2015)... ... August 29, 2015 , ... Vascular Health Sciences announced today ... and Arterosil HP, and that all claims and counterclaims have been irrevocably dismissed. ... (VHS) in the United States District Court for the Southern District of Texas ...
Breaking Medicine News(10 mins):Health News:FCPX Effects Developer, Pixel Film Studios, Releases ProDrop Particles. 2Health News:Heart Fit Clinic Sounds the Alarm on Forest Fire Smoke and Chronic Heart Disease in Calgary Area 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 3
... DALLAS, Nov. 20 Crdentia Corp. (OTC Bulletin,Board: ... the,promotion of Ms. Penny Kirsch to Vice President ... Human Resources Manager,for Crdentia and will continue to ... Kirsch will be responsible for all human resources ...
... SyntheMed, Inc. (OTC,Bulletin Board: SYMD), a biomaterials company ... delivery products, today,announced that President and CEO Robert P. ... Annual Healthcare Conference at the Palace,Hotel in New York ... EST. Lazard Capital Markets will host a web ...
... System Included in Molecular Imaging Zone, FORT ... (OTC Bulletin Board: IMDS) a pioneer in laser,optical ... will,feature breast cancer cases imaged with optical computed ... November 25 - 28. A CT,Laser Mammography (CTLM(R)) ...
... today the pricing of its public offering of 1,466,400 ... $3.50 per share. Uroplasty,has granted the underwriters a 30-day ... common stock at the offering price to cover,over-allotments. The ... to expand its sales and marketing organization in the ...
... save children,s lives runs through December 8 in all 6,200 ... ... be,participating in the fourth year of the St. Jude Children,s Research,Hospital(R) ... December 8. As part of this national,campaign, CVS/pharmacy has joined with ...
... protein albumin suggests worsening coronary artery disease, study finds ... small amount of a protein called albumin in the ... their risk of cardiovascular death, say U.S. researchers. , ... age 50 and older, with stable coronary artery disease ...
Cached Medicine News:Health News:Crdentia Announces Promotion of Penny Kirsch to Vice President of Human Resources 2Health News:Crdentia Announces Promotion of Penny Kirsch to Vice President of Human Resources 3Health News:Imaging Diagnostic Systems to Present Laser Breast Imaging Clinical Results at the 2007 Radiological Society of North America Scientific Assembly 2Health News:Imaging Diagnostic Systems to Present Laser Breast Imaging Clinical Results at the 2007 Radiological Society of North America Scientific Assembly 3Health News:Uroplasty, Inc. Announces Pricing of a Public Offering of Its Common Stock 2Health News:CVS/pharmacy Launches St. Jude Thanks and Giving(R) Campaign in Stores Nationwide 2Health News:CVS/pharmacy Launches St. Jude Thanks and Giving(R) Campaign in Stores Nationwide 3Health News:Urine Test Results Can Point to Heart Dangers 2
Flat Wire Stone Basket...
... Reichert MK1 Keratometer now utilizes ... consistent lighting, removing the need ... we didnt change are all ... made our Keratometer the worldwide ...
Agglutinating sera for serological identification of E. coli by slide and/or tube agglutination tests. Agglutinating sera are packaged 2 mL / vial....
... The innovative E.coli ... Pro-Lab offers definitive identification ... the use of a ... the possibility of cross-reactions ...
Medicine Products: